Last reviewed · How we verify
ISEPAMICIN
Isepamicin is a marketed antibiotic that inhibits bacterial cell wall synthesis, leading to cell death; it holds a niche position in the market with its key composition patent expiring in 2028. A key strength of isepamicin is its distinct mechanism of action compared to older aminoglycosides like gentamicin and kanamycin, which are off-patent and widely available as generics. The primary risk to isepamicin's market position is the competition from other same-class drugs, particularly tobramycin and amikacin, which are also patent-protected and have strong market presence.
At a glance
| Generic name | ISEPAMICIN |
|---|---|
| Drug class | isepamicin |
| Target | Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISEPAMICIN CI brief — competitive landscape report
- ISEPAMICIN updates RSS · CI watch RSS